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Anti-folate chemotherapy agents such as methotrexate and fluorouracil reduce proliferation of neoplastic cells by inhibiting DNA
synthesis. Paradoxically epidemiological data suggests an inverse relationship between dietary folate intake and incidence of colorectal
cancer (CRC). On the basis of this and other putative health benefits around 35% of the North American population take folic acid
supplements, in addition to natural food folates and fortified flour and cereal grains. Recently, randomised controlled trials
investigating folic acid as a secondary preventative agent in colorectal neoplasia have shed further light on the relationship between
folate and colorectal carcinogenesis, corroborating data from animal models indicating opposing effects dependent on the timing of
exposure in relation to the development of neoplastic foci. A ‘dual-modulator’ role for folate in colorectal carcinogenesis has been
proposed in which moderate dietary increases initiated before the establishment of neoplastic foci have a protective influence,
whereas excessive intake or increased intake once early lesions are established increases tumorigenesis. Functional polymorphic
variants in genes encoding key enzymes in the folate metabolic pathway add a further layer of complexity to the relationship between
folate and CRC risk. Here, we review the evidence concerning the efficacy and safety of folate as a potential CRC chemopreventive
agent.
British Journal of Cancer (2009) 100, 233–239. doi:10.1038/sj.bjc.6604823 www.bjcancer.com
Published online 16 December 2008
& 2009 Cancer Research UK
Keywords: folate; colorectal cancer; prevention
                                             
In the United States and United Kingdom colorectal cancer (CRC)
is respectively the second and third most common malignancy
(Jemal et al, 2007). Despite new therapeutic agents the prognosis
from CRC remains relatively poor, and the median survival of
optimally treated patients with advanced disease is B20 months.
Thus there is an urgent need to identify agents with CRC
chemopreventive activity to reduce the burden of this disease on
both the individual and wider society.
Folate is a natural constituent of foods such as green leafy
vegetables, legumes, and citrus fruits, and has attracted consider-
able attention as a potential CRC chemopreventive agent. Here, we
review our current understanding of the relationship between
folate and colorectal neoplasia development.
FOLATE METABOLISM, DNA METHYLATION AND
DNA SYNTHESIS
Folate is a generic term for a naturally occurring family of B-group
vitamins composed of an aromatic pteridine ring linked to
p-aminobenzoic acid and a glutamate residue (Shane, 1995).
Following absorption in the small intestine dietary food folates
undergo hydrolysis to methyltetrahydrofolate (methylTHF), the
predominant form of folate in plasma (Shane, 1995). Folic acid also
undergoes conversion to methylTHF, but this process becomes
saturated at doses of B270mg and at higher levels folic acid is
transported directly into the plasma (Sweeney et al, 2007). Hence,
daily ingestion of 400mg, a dose commonly used in supplements,
produces a sustained level of plasma folic acid.
Cellular folates act as donors and acceptors of methyl groups in
the biosynthesis of nucleotide precursors used for DNA synthesis,
and provision of methyl groups for methylation of DNA, RNA, and
proteins (Figure 1; Shane, 1995). These important cellular
processes lie at opposite ends of folate metabolism linked by
methylenetetrahydrofolate reductase (MTHFR) which catalyses the
irreversible conversion of 5,10-methyleneTHF to 5-methylTHF.
The MTHFR substrate, 5,10-methyleneTHF, is also a substrate for
the thymidylate synthase (TS) enzyme in the methylation of
deoxyuridine monophosphate (dUMP) to deoxythymidine mono-
phosphate (dTMP), which is the sole de novo source of thymidine
and the rate limiting step in DNA synthesis in mammalian cells
(Choi and Mason, 2002). 5,10-methyleneTHF is also used in the
production of formylTHF, which is in turn used in de novo purine
synthesis. The MTHFR product, 5-methylTHF, is the methyl group
donor for the remethylation of homocysteine to methionine
catalysed by the enzyme methionine synthase (MTR). Methionine
is adenylated to form S-adenosylmethionine (SAM), which is the
methyl group donor in methylation reactions, whereas SAM
inhibits the MTHFR enzyme providing a negative feedback control
loop.
Variation in the distribution of methyl groups through altered
folate metabolism impacts on both DNA methylation and DNA
synthesis, two crucial cellular processes in relation to neoplastic
transformation (Choi and Mason, 2002). Methylation of the
cytosine residues of cytosine–guanine dinucleotide pairs is an
important epigenetic determinant of gene expression and also has
a role in maintaining DNA stability. Hypermethylation of gene
promoter regions results in loss of tumour suppressor
gene function, whereas reduced ‘global’ methylation results in
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events (Eden et al, 2003). Long-term dietary folate deficiency in
humans results in global DNA hypomethylation in lymphocytes,
which is reversible on repletion of folate status (Jacob et al,
1998). Paradoxically studies in rodents have shown promoter-
specific hypermethylation increases in response to folate
deficiency (Pogribny et al, 1997). Through a reduction in the
availability of methyl groups for methylation of homocysteine to
methionine, folate deficiency leads to a rise in homocysteine
levels which in turn results in raised levels of S-adenosylhomo-
cysteine (SAH). S-adenosylhomocysteine is an inhibitor of
methylation reactions, and this is thought to underlie the reduced
global DNA methylation observed in individuals with low folate
status.
Reduced deoxythymidylate synthesis leading to uracil misin-
corporation during DNA synthesis provides a second mechanism
through which folate deficiency can disrupt DNA integrity and
promote carcinogenesis. Removal of a uracil base involves creation
of a single-strand DNA break, and where two adjacent uracil bases
lie on opposite strands a double-strand DNA break will occur
which are difficult to repair and are associated with an increased
cancer risk (McKinnon and Caldecott, 2007). Increased DNA uracil
content and chromosomal breaks occur in folate-deficient humans,
and both can be reversed by restoration of adequate folate status
(Blount et al, 1997).
The understanding that folate metabolism can reciprocally
influence both DNA synthesis and methylation has made
environmental and genetic variants that impact on this pathway
attractive candidates as cancer susceptibility factors. These include
dietary intakes of folate and folic acid, and functional polymor-
phisms in the genes coding for folate metabolism enzymes.
EPIDEMIOLOGICAL STUDIES OF FOLATE INTAKE
AND COLORECTAL CANCER RISK
Thirteen case–control studies and eight cohort studies have
examined the relationship between folate intake and CRC
(Giovannucci, 2002) with most reporting reductions in cancer
incidence in individuals with higher folate intake. A meta-analysis
of seven of the eight cohort studies indicated a 25% reduction in
CRC risk for subjects in the highest quintile of dietary folate intake
(from food only) compared with the lowest (Sanjoaquin et al,
2005). More recent studies, however, have not confirmed an
inverse relationship even in subjects with a relatively low mean
dietary folate intake (de Vogel et al, 2008, Sharp et al, 2008).
Subgroup analyses in the study by Sanjoaquin et al. (2005)
indicated a stronger protective effect for colon compared with
rectal cancer, whereas when total folate intake (food and
supplements combined) was examined there was no statistically
significant evidence for a protective effect of high intake for either
colon of rectal cancers. Further studies are required to clarify
whether this discrepancy between the effects of dietary and total
folate intake is genuine, but the finding might be a consequence of
greater confounding by other dietary factors when analysing the
association between CRC and dietary folate than that with total
folate. Alternatively, natural folates and synthetic folic acid may
have different impacts on the folate metabolic pathway.
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Figure 1 Schematic representation of folate metabolism illustrating the entry of natural folates and folic acid into the pathway, and flow of methyl groups
towards either DNA synthesis or DNA methylation. RFC, reduced folate carrier; hFR, human folate receptor; MTR, methionine synthase; MTHFR,
methylenetetrahydrofolate reductase; SHMT, serine hydroxymethlytransferase; TS, thymidylate synthase; THF, tetrahydrofolate; DHF, dihydrofolate; SAM,
S-adenosylmethionine; SAH, S-adenosylhomocysteine; dUMP, deoxyuridine monophosphate; dTMP, deoxythymidine monophosphate.
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sustained period to impact on CRC risk. Such an assertion is
supported by findings from the Nurses’ Health Study, a cohort
study with over 88000 female participants, which showed no
inverse association between CRC risk and supplementation when
taken for less than 5 years, a non-significant inverse association
when taken for 5–14 years, but a substantial and significant
75% risk reduction when taken for 15 years or more (Giovannucci
et al, 1998). A similarly long latency period between folic acid
supplementation and a reduction in risk of CRC was demonstrated
in an independent large cohort study (Jacobs et al, 2003), in which
regular supplement use at enrolment had no association with CRC
incidence whereas supplement use 10-years before enrolment was
significantly inversely associated.
Retrospective (Boyapati et al, 2004) and prospective
(Giovannucci et al, 1993) studies examining folate intake and risk
of colorectal adenoma (CRA), the major precursor lesion for most
CRC, also provide support for an inverse relationship between
folate exposure and colorectal neoplasia risk. In an analysis of two
cohort studies, the Nurses’ Health study and the Health Physicians
Follow-Up Study, significantly reduced risks were observed in both
women and men for individuals in the highest quintile of total
folate intake compared with the lowest (Giovannucci et al, 1993).
Difficulties in accurately estimating dietary folate intake have
prompted some investigators to analyse the relationship between
CRC risk and red blood cell or plasma folate levels. These variables
may provide a more accurate measure of folate status at the
expense of being more susceptible to short-term fluctuations in
dietary folate intake. A nested case–control study based on the
Women’s Health Study cohort reported a significant 50%
reduction in CRC risk in women in the highest quartile of plasma
folate compared with the lowest (Kato et al, 1999), and a similar
CRC risk reduction was observed in male participants with
adequate plasma folate levels compared to those with levels
indicating deficiency (o3ngml
 1) in the Physicians Health Study,
albeit non-significantly (Ma et al, 1997). However, more recent
studies have not supported an inverse association between plasma
folate and CRC risk (Van Guelpen et al, 2006, Otani et al, 2008).
A nested case–control study in the Northern Sweden Health and
Disease Cohort reported that subjects with over 4 years follow-up
and plasma folate levels in the highest quintile were at a 4-fold
increased risk of CRC compared with those in the lowest quintile
(Van Guelpen et al, 2006), whereas a Japanese cohort study
including 375 individuals diagnosed with CRC provided no
evidence of a relationship between plasma folate and CRC risk in
either men or women (Otani et al, 2008).
Other dietary factors apart from folate and folic acid may also
impact on folate metabolism, notably alcohol, choline, and
methionine. Alcohol is a folate antagonist interfering with folate
absorption and other aspects of folate metabolism, whereas choline
and methionine are important dietary sources of methyl groups,
estimated to contribute respectively 60 and 20% of the total
ingested by humans, compared with 20% derived from folate. Diets
high in alcohol and low in folate and methionine are considered
‘methyl-poor’ whereas those low in alcohol and high in folate and
methionine are ‘methyl-rich’. Studies that have analysed combina-
tions of these dietary components have generally found increased
risks of CRC and CRA for ‘methyl-poor’ diets compared with
‘methyl-rich’ providing further evidence of a protective role for
efficient folate metabolism in colorectal neoplasia (Giovannucci,
2002).
Collectively, the evidence from epidemiological studies is at best
only suggestive of an inverse relationship between dietary folate or
supplemental folic acid intake and CRC risk. Important questions
remain unresolved, however, including the optimal level of
increased dietary or supplemental folate intake to minimise CRC
risk, the duration of increased exposure required, whether cancer
risks are attenuated in both men and women and in both the colon
and rectum, and whether dietary folates and supplemental folic
acid have similar inverse associations. It is notable that the recent
World Cancer Research Fund/American Institute for Cancer
Research report into food, nutrition, physical activity and the
prevention of cancer judged foods containing folate to have only
‘limited-suggestive’ evidence of a protective effect against CRC
(WCRF/AICR, 2007).
FUNCTIONAL POLYMORPHISMS IN FOLATE
METABOLISM GENES
A number of common genetic variants alter either the cellular
levels or functioning of folate metabolism enzymes, and are likely
to play an important role in determining an individual’s response
to changes in dietary folate intake. The C677T variant of the
MTHFR gene has been extensively investigated for an association
with CRC and CRA risk and interactions with intakes of folate,
other B vitamins, and alcohol. Individuals with homozygous 677TT
genotype, who comprise B11% of Caucasians, have only 35% of
the normal activity of this pivotal enzyme, resulting in channeling
of methyl groups towards DNA synthesis at the expense of DNA
methylation (Chen et al, 1996). When genotype is considered in
isolation, 677TT individuals show a modest reduction in CRC risk
compared to those with wild-type 677CC genotype (Hubner and
Houlston, 2007), whereas CRA risk does not appear to be
significantly influenced by MTHFR C677T genotype (Sharp and
Little, 2004). Studies stratifying by both genotype and methyl
status, however, have indicated a more complex relationship with
677TT individuals being at reduced CRC risk if they also have high
methyl status (low alcohol, high folate), but at increased risk if
their methyl status is low (high alcohol, low folate) (Chen et al,
1996; Ma et al, 1997). These interactions are not universally
reported in small case–control series, although a recent well-
powered case–control study also indicated interactions between
MTHFR C677T genotype and folate status or alcohol intake in
determining CRC risk (Le Marchand et al, 2005).
The complex relationship between folate intake and CRC risk
may be further modulated by other functional polymorphisms
impacting on folate metabolism. These include the MTHFR
A1298C variant which also confers a reduced MTHFR enzyme
function, the thymidylate synthase promoter (TSER) and the 30
untranslated region (TS 1494del6) variant (Sharp and Little, 2004;
Ulrich et al, 2005). Furthermore, recent data indicates folate may
have differential influences on the development of CRC caused by
mis-match repair deficiency and chromosomal instability (Hubner
et al, 2007).
To date, studies investigating the relationships between the
multiple genetic and dietary factors that impact on folate
metabolism have had sample sizes at least one order of magnitude
too small to convincingly confirm or refute potential gene–gene or
gene–nutrient interactions in determining colorectal neoplasia
risk. It is highly probable, however, that studies seeking to define
the relationship between folate intake and CRC risk that do not
stratify subjects by genotype at two or three polymorphic loci at
the very least will miss important disease–nutrient associations in
subgroups of the population defined by these genetic variants.
EVIDENCE FROM ANIMAL MODELS
The relationship between folate and intestinal neoplasia has been
investigated with two classes of rodent model; animals injected
with chemical colorectal carcinogens such as dimethylhydrazine or
azoxymethane, and animals genetically predisposed to intestinal
neoplasia (Cravo et al, 1992; Kim et al, 1996; Song et al, 2000a,b).
Studies using chemical carcinogens reported that moderate folate
deficiency enhanced colorectal carcinogenesis whereas folate
supplementation had an opposing effect (Cravo et al, 1992; Kim
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basal daily requirement did not confer additional benefit however,
and exceptionally high levels of folate supplementation (up to 1000
times basal requirement), were found to promote the development
of aberrant crypt foci and early neoplasms (Kim et al, 1996).
In APC
Min mice randomly assigned to receive diets of varying
folate content after weaning, the number of small intestinal
adenomas found at 3 months was inversely related to both the level
of dietary folate and serum levels of folate, again corroborating
evidence from humans (Song et al, 2000a). At 6 months however,
mice fed a folate-deficient diet had fewer distal small intestinal
adenomas compared with folate-supplemented animals, and the
number of distal adenomas was positively associated with serum
folate levels suggesting an inhibitory effect of folate deficiency on
established distal small intestinal adenomas (Song et al, 2000a).
A similar study using APC
þ/ MSH2
 /  mice also showed
differential associations of dietary folate depending on the timing
of intervention (Song et al, 2000b). When commenced before the
establishment of neoplastic foci, folate supplementation at four
times basal requirement resulted in a 3-fold reduction in the
number of small intestinal adenomas compared with a moderately
folate-deficient diet. Dietary folate manipulation after the devel-
opment of neoplastic foci had the opposite effect however, with
deficiency significantly decreasing the number of adenoma
compared with supplementation.
Histological, clinical, and molecular genetic differences prevent
direct extrapolation of the findings from both types of animal
models to human CRC. For example, the carcinomas developing
in the chemical carcinogen models often arise from flat foci of
dysplasia rather than adenomas, whilst in both APC
Min and
APC
þ/ MSH2
 /  mice the predominant phenotype is small
intestinal rather than colonic adenomas and animals do not
develop adenocarcinomas as they die from florid polyposis and
intestinal obstruction (Song et al, 2000a, 2000b). In genetic models,
the aberrant cypt foci (ACF) to adenoma progression typical of
sporadic human CRA is not established, and KRAS mutations
commonly observed in human CRCs are not detected in APC
Min
mice polyps (Song et al, 2000a). Despite such limitations, these
studies provide further evidence that the relationship between
dietary folate intake and intestinal neoplasia is not straightforward
with both the level and timing of exposure being important
determinants. These observations have played an important role in
the development of a hypothesis proposing a ‘dual-modulator’ role
for folate in CRC, with a protective influence of moderate dietary
increases initiated before the establishment of neoplastic foci, but a
detrimental influence of excessive intake or increased intake in the
setting of pre-established neoplastic foci (Kim, 2004; Ulrich and
Potter, 2007). Early prevention of tumorigenesis is most likely
because of protection against DNA damage by maintaining
adequate methyl groups for DNA methylation and for purine
and pyrimidine synthesis, whereas the probable mechanism
underlying the later enhanced tumour growth is an increased
provision of nucleotide precursors to rapidly replicating neoplastic
cells allowing accelerated proliferation and growth.
RANDOMISED STUDIES OF FOLIC ACID
INTERVENTION IN HUMANS
Randomised controlled trials of potential CRC preventive agents in
the primary preventive setting would require a prohibitively large
number of participants because of the long latent period and
relatively low population incidence of the disease. For this reason a
number of dietary and other interventions have been investigated
in the secondary preventive setting of CRA recurrence. The CRA
recurrence paradigm has provided evidence of chemopreventive
activity for calcium supplements, aspirin, and COX-2 selective
NSAIDs, and an absence of activity for wheat bran high-fibre cereal
supplement, ursodeoxycholic acid, and a low-fat high-fibre high-
fruit diet.
Very recently the results of two large, multi-centre, phase III
studies – The Aspirin/Folate Polyp Prevention study and the
United Kingdom Colorectal Adenoma Prevention study – have
been published (Table 1; Cole et al, 2007; Logan et al, 2008). Both
studies used a ‘factorial’ design in which participants were not only
randomised to folic acid and placebo, but also aspirin and placebo,
allowing the effects of both agents to be investigated simulta-
neously. The US-based study reported by Cole et al (2007)
randomised individuals to 1000mg folic acid daily for 3 years, and
recurrence data were available for 987 individuals. The incidence
of at least one CRA, the primary end point of the study, was
essentially the same in the folic acid and placebo arms; however,
subjects receiving folic acid showed non-significant increases of 32
and 20%, respectively in the secondary end points of incidence of
Table 1 Details of published randomised double-blind placebo-controlled trials of folic acid for prevention of colorectal adenoma recurrence
Intervention
Placebo Folic acid
Study Year
a Country
Folic acid
dose (lg/day)
Duration
(years) N
b Outcome
N outcome/
total (%)
N outcome/
total (%) RR (95%CI)
c
Paspatis et al NS Greece 1000 1 60 Adenoma incidence 11/29 (38) 7/31 (23) 0.48 (0.13–1.68)
d
2 60 Adenoma incidence 8/29 (28) 4/31 (13) 0.39 (0.08–1.72)
d
Cole et al 1994–98 USA 1000 3 987 Any adenoma incidence 206/486 (42.4) 221/501 (44.1) 1.04 (0.90–1.20)
Advanced adenoma incidence
e 42/486 (8.6) 57/501 (11.4) 1.32 (0.90–1.92)
No of adenomas 1–2 168/486 (34.6) 174/501 (34.7) 1.00 (0.85–1.19)
X3 38/486 (7.8) 47/501 (9.4) 1.20 (0.80–1.81)
6–8 607 Any adenoma incidence 113/304 (37.2) 127/303 (41.9) 1.13 (0.93–1.37)
Advanced adenoma incidence
e 21/304 (6.9) 35/303 (11.6) 1.67 (1.00–2.80)
No of adenomas 1–2 100/304 (32.9) 97/303 (32.0) 0.97 (0.77–1.22)
X3 13/304 (4.3) 30/303 (9.9) 2.32 (1.23–4.35)
Logan et al 1997–2001 UK 500 3 853 Any adenoma incidence 105/421 (24.9) 115/432 (26.6) 1.07 (0.85–1.34)
Advanced adenoma incidence
e 52/421 (12.4) 52/432 (12.0) 0.98 (0.68–1.40)
aTime period of participant recruitment.
bNumber of subjects available for outcome assessment.
cRelative risk and 95% confidence interval.
dCalculated from published raw data.
eAdvanced adenoma defined as adenomas X1cm in diameter, adenomas with villous or tubulovillous histology, adenomas with severe dysplasia, or diagnosis of colorectal
cancer; NS, not stated.
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Participants were invited to continue in the trial for a further
3–5 years, and those that agreed could either continue study
medication in their original randomised group or discontinue
medication and simply be followed-up for further end points.
At six to eight years of follow-up 607 individuals remained for
analysis of recurrence data, 501 of whom had continued
randomised medication. In this second follow-up interval indivi-
duals in the folic acid arm showed a non-significant 13% increase
in the incidence of at least one CRA recurrence, a 63% increase in
advanced CRA, and the number of subjects with three or more
CRA was more than doubled. In participants with end point
information for both follow-up intervals the adenoma rate (any
CRA in either interval) was 65.5% in the placebo group and 71.3%
in the folic acid group (RR¼1.09; 95% CI: 0.98–1.21). These
results indicated that a daily dose of 1000mg folic acid did not
result in a reduction in CRA recurrence; however, the more
concerning conclusion was a possible increased risk of advanced
CRA or multiple CRA. A plausible explanation for these
unexpected findings is that folic acid promoted the growth of
pre-existing ACF or microscopic adenoma that were not visible at
entry colonoscopy, in a similar manner to that observed in the
genetic models discussed above (Ulrich and Potter, 2007). Of
further concern was a significant increase in cancers other than
CRC, largely attributable to an elevated risk of prostate cancer
(Cole et al, 2007).
The second large RCT of folic acid in CRA recurrence also failed
to show an inverse association, but did not provide confirmatory
evidence of a positive association (Logan et al, 2008). This UK-
based study randomised individuals to 500mg daily folic acid or
placebo for 3 years, used similar end points, and reported
recurrence data for 853 participants. Subjects who received folic
acid had only a very minor increase in incidence of one or more
adenoma, and no increase in advanced adenoma. Longer term
follow-up data are not available from this trial. Possible reasons for
the discrepancies with the findings of the US trial are the lower
dose of folic acid used in the UK trial, and a likely lower dietary
intake of folate because of the absence of mandatory folate
fortification of flour in the United Kingdom.
Although inconclusive, the results from CRA recurrence studies
suggest that folic acid supplementation in individuals at increased
risk of CRC on the basis of previous or existing CRA is unlikely
to be beneficial for CRC prevention, and could possibly be
detrimental, particularly at high doses. As 25–50% of North
Americans over the age of 50 harbour CRAs even only a minor
increase in risk could translate to a significant public health
concern. The absence of a clear association between MTHFR
C677T genotype and CRA incidence may make interpretation of
associations between folic acid intake and CRA recurrence risk in
relation to CRC risk more complex, although there is evidence that
MTHFR polymorphism genotypes influence CRA recurrence in a
similar manner to CRC incidence (Martinez et al, 2006).
FOLATE FORTIFICATION AND CRC INCIDENCE
Folic acid supplements taken in the peri-conceptual period have
proven benefits in reducing neural tube defects (NTDs; MRC
Vitamin Study Research Group, 1991). In March 1996, the US Food
and Drug Administration issued a mandate requiring fortification
of flour with folic acid (140mg folic acid per 100g flour) with the
aim of reducing NTDs. Although the mandate specified that
fortification should be in place by no later than January 1998, in
practice most large food companies commenced fortification in
early 1996. Fortification was also mandated in Canada although
was not allowed to commence before December 1996. Mandatory
folic acid fortification has been highly successful in achieving its
primary aim with reductions in the incidence of NTDs in North
America of 20–50%. The typical intakes of folic acid from fortified
foods were more than two times the level originally predicted
however, and population-based studies indicated that plasma
folate levels in adults increased B2-fold following fortification.
A recent study has highlighted a temporal relationship between
the onset of folic acid fortification and rises in the incidence
of CRC in both the United States and Canada (Mason et al, 2007).
The analyses by Mason et al (2007) demonstrate that in the early
1990s the age-adjusted incidence of CRC declined moderately
in both countries (Figure 2). Between 1995 and 1996 however, the
incidence rate in the United States showed a slight increase
followed by more marked increases in 1997 and 1998. A similar
change occurred in Canada, but with a time lag of B1 year
compared to the United States, with a sharp increase occurring
between 1997 and 1998. In both instances the deviations in CRC
incidences from the pre-existing trends were highly statistically
significant, occurred in both men and women, and resulted in
an excess of B5 cases per 100000 individuals. Mason et al.
hypothesized that folic acid fortification was responsible for these
increases in CRC rates but because of limitations in the datasets a
causal relationship could not be established. Nevertheless, these
observations are provocative and cannot be accounted for by
changes in the use of colonoscopy or other screening procedures
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Figure 2 Age-adjusted CRC incidence from 1986 to 2002 in the
United States (A) and Canada (B) based on nationally representative
databases (for Canada, the incidence is based on the average of the
rates for men and women). Open circles represent data points.
A nonparametric loess smoother was fitted to the data and the grey
areas represent 95% confidence bands. (Reproduced by the kind
permission of the American Association of Cancer Research from Mason
et al, 2007).
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2007). It should be noted, however, that the temporary increase in
CRC incidence between 1996 and 1998 occurred against a
background of gradually declining incidence over the decade as
a whole which may in part be accounted for by increasing
population intakes of folate-rich foods and folic acid supplements.
CONCLUSIONS AND FUTURE DIRECTIONS
Recent evidence suggests that an individual who chooses to
increase their folate intake with folic acid supplements may
experience either beneficial or detrimental effects in terms of CRC
risk depending on the existence of early neoplastic lesions in their
colorectal epithelium. This relationship may be further influenced
by their genotype, and their prior level of dietary folate intake.
The net effect on CRC incidence of increased folate intake across
the population remains unknown, and depends on whether the
preventive influences against neoplastic transformation in the
normal colorectal epithelium are out-weighed by later enhance-
ment of the growth of early neoplastic lesions that may develop
despite early protection. Thus the efficacy and safety of folate in
CRC prevention remains undetermined and will depend on the
relative size of these two potential effects, the level of increased
exposure, and the nature of the population exposed in terms of age
and other CRC risk factors. Only randomised primary preventive
trials can provide definitive data to address these issues, and would
ideally recruit participants of young age who are unlikely to have
pre-existing early colorectal lesions. Although such studies will be
logistically challenging and require a very significant investment of
resources, the widespread voluntary usage of folic acid supple-
ments coupled with mandatory folic acid fortification in some
countries make clarification of both the efficacy and safety of these
interventions a high priority. In the meantime, recommendations
should be based on a synthesis of available data from observational
data, genetic studies, mechanistic and animal studies, and
randomised secondary preventive studies. These issues should be
considered carefully by government authorities in the United
Kingdom and other countries where mandatory fortification is
currently being considered.
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